Valence8 Us LP Crispr Therapeutics Ag Transaction History
Valence8 Us LP
- $213 Billion
- Q1 2025
A detailed history of Valence8 Us LP transactions in Crispr Therapeutics Ag stock. As of the latest transaction made, Valence8 Us LP holds 13,100 shares of CRSP stock, worth $484,045. This represents 0.26% of its overall portfolio holdings.
Number of Shares
13,100Holding current value
$484,045% of portfolio
0.26%Shares
0 transactions
| Quarter | Operation | Price Per share | shares change | shares Held | SEC Form |
|---|
Others Institutions Holding CRSP
# of Institutions
479Shares Held
64.2MCall Options Held
2.15MPut Options Held
1.92M-
Cathie Wood Ark Investment Management LLC | St. Petersburg, Fl10.2MShares$376 Million3.73% of portfolio
-
Capital International Investors Los Angeles, CA6.07MShares$224 Million0.04% of portfolio
-
T. Rowe Price Investment Management, Inc. Baltimore, MD3.8MShares$140 Million0.09% of portfolio
-
Black Rock Inc. New York, NY2.78MShares$103 Million0.0% of portfolio
-
Nikko Asset Management Americas, Inc.2.54MShares$93.8 Million1.16% of portfolio
About CRISPR Therapeutics AG
- Ticker CRSP
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 78,009,296
- Market Cap $2.88B
- Description
- CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious diseases using its proprietary Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. Its CRISPR/Cas9 is a gene editing technology that allows for precise directed changes to genomic DNA....